drugset / Trial / NCT00849069
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease. Subjects will be vaccinated 3 times with an interval of respectively 2 and 10 months.
Timeline
- Start
- 2009-03-12
- Primary completion
- 2009-04-07
- Completion
- 2009-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK2231395A | Vaccine | — | Intramuscular |
| Comparator | TwinrixTM | Unknown | — | Intramuscular |